RXi Pharmaceuticals of Marlborough said Thursday it has begun its first clinical trial of a compound to evaluate its ability to prevent retinal scarring.
The study will evaluate the safety of RXI-109 as well as its ability to prevent the progression of retinal scarring, a harmful consequence of several eye diseases. The study will use subjects with advanced neovascular, age-related macular degeneration.
RXi Pharmaceuticals focuses on research in dermatology and ophthalmology.
The company describes RXI-109 as a self-delivering compound developed to target connective tissue growth factor, a key regulator of scar formation in the skin and known to be involved in retinal scarring. RXI-109 is also currently being evaluated in clinical dermatology trials.
